A federal appellate court for the first time since 2009 has dismissed claims against a name-brand drug manufacturer pursuant to the "impossibility" preemption doctrine.
The agency lays down potential ground rules on the use of commercial drones.
Lawyers should consider the content of their communications carefully as a lawyer's role is not without limits.
By Karen Woodward and Mary Beth Buckley
FDA and stakeholders hone in on the security of interoperable medical devices.
By James M. Beck
With the increasing prevalence of third-party insurance, the recovery of medical expenses is not as straightforward as it used to be.
By M. Joseph Winebrenner
An introduction to standing and judicial estoppel for young lawyers.
Litigator Donnie Winningham discusses outlines reason why educational malpractice claims are rejected and how to best defend them. (10:30 min)
Kristin Beckman explains that by focusing your strategy on the burden of proof, you can limit the scope of exhibits, leading to a more manageable and focused case. (06:22 min)
Veteran litigator Douglas Maag details how U.S. economic and trade sanctions can affect the handling of mass-tort claims. (8:13 min)
Examining the holding in this newly announced decision and what it may mean for future parens patriae actions and other types of quasi-class actions or mass actions. (56:12)
Featuring a unique group of lawyers and non-lawyers to provide a fact-based peek into the future, including presentations and an interactive discussion among the panelists. (1:01:42)
Learn about the significance of the Barltett decision and its impact on the Supreme Court's preemption holdings. (57:33)
The latest edition of Mass Torts is now available.
Mass Torts Leadership
|Cochairs||Web Editor||Newsletter Editor|
Kansas City, MO
Leadership Development & Young Lawyer Outreach Liaison
Sun Valley, CA